Cytokinetics Secures EU Approval for HCM Treatment MYQORZO
Event summary
- Cytokinetics’ MYQORZO (aficamten) has received European Commission approval for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults.
- The approval is based on results from the SEQUOIA-HCM Phase 3 clinical trial, published in the New England Journal of Medicine.
- First commercial launch is expected in Germany in Q2 2026.
- MYQORZO demonstrated a 1.76 mL/kg/min increase in peak oxygen uptake (pVO2) compared to placebo in the SEQUOIA-HCM trial.
- The drug has also been approved in the U.S. and China for the same indication.
The big picture
The approval of MYQORZO represents a significant advancement in the treatment of oHCM, a relatively rare but debilitating condition affecting approximately 1 in 500 Europeans. The drug’s novel mechanism of action – cardiac myosin inhibition – establishes a new therapeutic approach, potentially displacing existing treatments and capturing a meaningful share of a niche market. Cytokinetics’ success in securing approvals across major markets (US, China, EU) positions them as a leader in this emerging therapeutic area.
What we're watching
- Commercial Execution
- The initial German launch will be a key test of Cytokinetics’ commercial infrastructure and ability to penetrate a new market, particularly given the specialized nature of HCM treatment.
- Adverse Events
- Continued monitoring of left ventricular ejection fraction (LVEF) reductions and other adverse events will be crucial to assess long-term safety and manage potential label updates.
- Pipeline Expansion
- The progress of clinical trials for MYQORZO in non-obstructive HCM (ACACIA-HCM) and pediatric populations (CEDAR-HCM) will determine the drug’s long-term revenue potential and market reach.
Related topics